Bristol Myers Squibb stock falls 1.58% for second straight session
Updated
Updated · MarketWatch · Apr 27
Bristol Myers Squibb stock falls 1.58% for second straight session
9 articles · Updated · MarketWatch · Apr 27
Shares closed at $57.78 on Monday, underperforming competitors as trading volume reached 10.7 million, below the 50-day average.
The stock ended 8.12% below its 52-week high of $62.89 set on March 2, 2026.
While the S&P 500 rose 0.12% and the Dow Jones fell 0.13%, Bristol Myers Squibb lagged behind industry peers Johnson & Johnson, Pfizer, and Abbott Laboratories.
Does a 4.3% dividend yield make this stock a safe bet despite looming revenue cliffs?
Can the company's 'Growth Portfolio' ramp up fast enough to avert a major downturn?
How will the outcome of the Cobenfy Alzheimer's trial redefine the company's future?
Is Bristol Myers' $14 billion Alzheimer's drug bet a genius move or a desperate gamble?
With key patents expiring, can BMY's new drug pipeline truly replace its blockbuster revenues?